Adapt Pharma holds a virtual monopoly on the first FDA-approved nasal form of Naloxone, leading to speculation about a future IPO driven by heavy public relations. A shift in discussion critiques a Viceland documentary regarding the burka ban in France. The documentary is criticized for focusing on schoolgirls' clothing choices rather than addressing the cultural tensions in European "no-go zones."
